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Urotensin-II peptidomimetic incorporating a
non-reducible 1,5-triazole disulfide bond reveals a
pseudo-irreversible covalent binding mechanism
to the urotensin G-protein coupled receptor†
Salvatore Pacifico,a Aidan Kerckhoffs,b Andrew J. Fallow,c Rachel E. Foreman,c
Remo Guerrini,a John McDonald,d David G. Lambert*d and Andrew G. Jamieson *b
The urotensin-II receptor (UTR) is a class A GPCR that predominantly binds to the pleiotropic cyclic
peptide urotensin-II (U-II). U-II is constrained by a disulfide bridge that induces a β-turn structure and
binds pseudo-irreversibly to UTR and is believed to result in a structural rearrangement of the receptor.
However, it is not well understood how U-II binds pseudo-irreversibly and the nature of the reorganiz-
ation of the receptor that results in G-protein activation. Here we describe a series of U-II peptido-
mimetics incorporating a non-reducible disulfide bond structural surrogate to investigate the feasibility that
native U-II binds to the G protein-coupled receptor through disulfide bond shuffling as a mechanism of
covalent interaction. Disubstituted 1,2,3-triazoles were designed with the aid of computational modeling
as a non-reducible mimic of the disulfide bridge (Cys5–Cys10) in U-II. Solid phase synthesis using CuAAC
or RuAAC as the key macrocyclisation step provided four analogues of U-II(4–11) incorporating either a
1,5-triazole bridge (5, 6) or 1,4-triazole bridge (9, 10). Biological evaluation of compounds 5, 6, 9 and 10
was achieved using in vitro [125I]UII binding and [Ca2+]i assays at recombinant human UTR. Compounds 5
and 6 demonstrated high affinity (KD ∼ 10 nM) for the UTR and were also shown to bind reversibly as pre-
dicted and activate the UTR to increase [Ca2+]i. Importantly, our results provide new insight into the
mechanism of covalent binding of U-II with the UTR.
Introduction
G-Protein Coupled Receptors (GPCRs) are important trans-
membrane proteins responsible for numerous cell-signaling
processes. They play a fundamental role in normal physiology
and their dysfunction is implicated in diseases including
cardiovascular, neurological and reproductive among others.1
In view of this, GPCRs have become a major focus of the scien-
tific community and are valuable drug targets. The G-protein
cycle is initiated through the interaction of ligand molecules
including hormones and neurotransmitters with the receptor.
A conformation change of the receptor then causes G-protein
activation and leads to intracellular signaling cascades.2
However, knowledge of the precise mechanism of receptor–
ligand binding and structural rearrangement of GPCRs is
lacking in many examples. There has been a recent explosion
in GPCR structural biology research facilitated by the lipidic
cubic phase method, mutation stabilized structures and
advances in cryo-EM.3 This has highlighted commonalities in
GPCR structural rearrangement resulting in activation,
however this research has also demonstrated the many differ-
ences in ligand binding mechanisms. Despite these advances,
full understanding of the scope and complexity of GPCR
ligand interactions and their role in cell signaling is still to be
determined.
The urotensin-II receptor (UTR) is a subclass 1A GPCR with
both central and peripheral expression. Recent evidence
suggests that UTR isoforms are found in rat heart nuclear
extract and can also play a role in the regulation of gene
expression.4 UTR has two endogenous cyclic peptide ligands:
urotensin-II (U-II) and urotensin-II related peptide (URP)
(Fig. 1A and B).5,6 Together U-II and URP regulate the urotensi-
nergic system and thus play a key role in the regulation of a
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number of human pathologies; the most well studied being
cardiovascular. For example U-II is elevated in patients with
heart failure.7 Despite this recent research, there is still a lot to
learn to fully understand the nature of ligand recognition and
the complexity of UTR involvement in cell signaling.
Consequently, the development of peptidomimetics based
on U-II that act as agonists or antagonists of the UTR would be
extremely useful tools to investigate the physiological role of
the U-II/UTR system.
Structure–activity-relationship studies have identified the
functionality and conformational preferences of U-II and URP
that are responsible for mediating the molecular recognition
event with the UTR. All U-II and URP analogues incorporate a
conserved C-terminal cyclic hexapeptide that is structurally
constrained by a disulfide bridge. This cyclic hexapeptide
sequence adopts a β-turn in SDS micelle solution as deter-
mined by NMR spectroscopy and is proposed as the bioactive
conformation.8
Several SAR studies have identified the amino acid residues
that are essential for biological activity.9–12 An investigation of
truncated analogues of U-II provided an octapeptide U-II(4–11)
as the minimum fragment that retained full biological activity
(Fig. 1C). The length and sequence of the U-II N-terminal resi-
dues vary across animal species. The role of the N-terminal tail
is not well understood but may be involved in facilitating
biased agonism.8 The intracyclic Trp7-Lys8-Tyr9 triad has
been identified as the pharmacophore and is associated with
biological activity.9,10 Most medicinal chemistry programs
have thus focused on this amino acid triad within the
cyclic hexapeptide sequence and have produced potent UTR
peptidomimetic agonists: P5U and UPG84 (Fig. 1D);13 and also
antagonists such as urantide.14,15
The U-II-UTR system is particularly intriguing as peptide
binding is irreversible such that under normal physiological
conditions (circulating U-II) the receptor is probably function-
ally silent.15 As a consequence, receptor function may be
driven, not by increased peptide production, rather by modu-
lation of receptor expression. To an extent UTR in primary
ex vivo tissue will represent a partially desensitised state. Current
peptide ligands are based on U-II and as such all display the
unwanted effect of irreversibility; production of reversible
U-II-like molecules is a current unmet need in the field.
Most irreversible agonists permanently bind to their recep-
tor either by forming a covalent bond at the binding site or by
binding with a dissociation rate of zero, relative to the limit of
detection. U-II is a very tight binder of the UTR (KD 170 pM),
however several analogues of U-II have been developed with
lower binding affinity yet presumably are also pseudo-irrevers-
ible ligands.15 This intriguing effect led us to speculate
whether the U-II disulfide bond that constrains the bioactive
amino acid triad could undergo disulfide bond shuffling at the
binding site and subsequently covalently cross-link to cysteine
residues on the receptor.
A two-state acid (–SH)/base (–S–S–) model for GPCRs has
previously been reported.16 Evidence for this model was
obtained from the observation that the reducing agent DTT
causes functional activation of the 5-HT2A GPCR in the pres-
ence or absence of agonist, and that the binding of agonists,
but not antagonist, is pH dependent.
No X-ray crystal structure is available of the UTR, however
the high-resolution crystal structure of human δ-opioid recep-
tor (h-DOR, PDB ID: 4n6h)17 has previously been shown to be
a high quality template to model the UTR.8 The h-DOR struc-
ture cannot provide the exact position of the inter-loop di-
sulfide bond, however given the structural homology between
h-DOR and UTR, an assumption of the general location of this
structural motif may be gained. We were therefore extremely
gratified to observe that UTR incorporates a disulfide bond
between extracellular loop 1 (Cys123) and loop 2 (Cys199) (ESI
Fig. S1†).18,19
Computation docking experiments have previously
suggested that the U-II and URP binding site is between extra-
cellular loops 2 and 3 occupying the hydrophobic cavity at the
end of the helix bundle. Upon binding, disulfide bond
shuffling is therefore possible and may result in a confor-
mational change in the receptor and facilitate the observed
cellular internalization. The reducing environment within the
cytosol provides a mechanism for ligand release and recycling
of the receptor at the nuclear membrane. To investigate this
possibility, we designed a U-II peptidomimetic incorporating a
non-reducible disulfide bond surrogate with the aim of devel-
oping a reversible UTR agonist.
The development of synthetic disulfide bond mimics is a
challenge in peptide chemical biology. Technologies that effec-
tively mimic disulfide bonds open the possibility of developing
chemical probes that are resistant to reduction by glutathione
Fig. 1 Structures of (A) urotensin-II, (B) urotensin II related peptide, (C)
urotensin-II (4–11) and (D) synthetic agonist P5U.
Organic & Biomolecular Chemistry Paper
This journal is © The Royal Society of Chemistry 2017 Org. Biomol. Chem., 2017, 15, 4704–4710 | 4705
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
2 
M
ay
 2
01
7.
 D
ow
nl
oa
de
d 
on
 1
7/
10
/2
01
7 
12
:5
5:
37
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
and are thus more stable under physiological conditions.
Designing synthetic functionality that accurately mimics the
Cβ–Sγ–Sγ–Cβ atoms in combination with the correct spacing of
the Cα has proven difficult to achieve.
The most successful strategies to mimic a disulfide bond to
date include cystathionine (CH2–S, Ctt), diselenide (Se–Se),
selenylsulfide (Se–S) and ditelluride (Te–Te) bonds.20 However,
multiple steps are required for their preparation and so their
use has been limited.21 Other synthetic disulfide bond surro-
gates that have been developed include thioether and olefin-
based isosteres.22–25 However thioethers require multistep syn-
thesis utilizing complex orthogonal protecting group strat-
egies. Olefin-based isosteres rely on ring-closing metathesis
(RCM) reactions that give cis/trans isomers, and required a sub-
sequent palladium-catalyzed hydrogenation step to access a
suboptimal, conformationally flexible alkane bridge.
Analogues of U-II incorporating a macrocyclic lactam in
place of the disulfide bridge have been reported, although
with reduced bioactivity compared to U-II indicating that the
lactam functionality is not an accurate mimic of the disulfide
bridge.26,27 Conformationally constraining the Cys5–Cys10 di-
sulfide bridge within U-II(4–11), by replacing Cys5 with penicil-
lamine (β,β-dimethyl cysteine) has given the most potent UTR
agonists reported to date (Fig. 1D).13
Disubstitiuted 1,2,3-triazoles have been used extensively in
peptides as surrogates for trans-amide bonds.28 1,2,3-Triazoles
can be prepared as either the 1,4-isomer using a Copper-
Catalyzed Azide–Alkyne Cycloaddition (CuAAC); or as the 1,5-
isomer using a Ruthenium-Catalyzed Azide–Alkyne
Cycloaddition (RuAAC). Several examples of bioactive peptides
incorporating a 1,4-disubstituted 1,2,3-triazole as a disulfide
bond mimic have been reported.29 However, in some instances
it has been ineffective and caused structural unfolding leading
to reduced biological activity.30 Kolmer was first to describe
the use of a 1,5-disubstitiuted 1,2,3-triazole as a disulfide
bond mimic. In this seminal work the disulfide bond within a
macrocyclic sunflower trypsin inhibitor-I was replaced by a 1,5-
triazole and the resulting peptidomimetic retained biological
activity.31
Herein, we describe the development of a series of U-II
(4–11) peptidomimetics that incorporate a triazole bridge to
investigate whether the disulfide bridge of U-II could be
responsible for the pseudo-irreversible binding mechanism.
The most potent of these peptidomimetics is compound 6,
which we refer to as Urotriazole because it incorporates a 1,5-
triazole bridge that accurately mimics the disulfide bridge in
U-II. Urotriazole 6 is a potent UTR agonist and was found to be
a reversible binder in a radioligand U-II displacement assay
with a full agonist profile at UTR.
Results and discussion
The NMR structure of U-II(4–11) in SDS micelle solution was
used to computationally model the peptidomimetics and
inform the design process (Fig. 2). Rather than mimicking the
Cβ–Sγ–Sγ–Cβ disulfide bond we chose to design a bridge that
would accurately mimic the orientation of the two Cα–Cβ
bonds. To assess the effectiveness of the triazole bridges
corresponding to compounds 5, 6, 9 and 10, computational
overlays with the U-II NMR structure were created and the root
mean square deviations (RMSD) calculated. In initial designs
it was apparent that a symmetrical triazole bridge incorporat-
ing one methylene was too short to act as an effective surro-
gate. RMSD for structures corresponding to compounds 9 and
10 were a disappointing 1.173 Å and 0.783 Å, respectively.
Addition of a second methylene group to the azide derived
side of the bridge proved more effective. Overlay of compound
5, incorporating a 1,5-triazole provided a RMSD of 0.607 Å.
The optimal design was Urotriazole 6, incorporating a 1,5-tri-
azole that gave RMSD of 0.182 Å.
Chemistry
Linear peptides 1 and 2 were synthesized by microwave-
assisted Fmoc solid phase peptide synthesis (SPPS) on
ChemMatrix™ 2-chlorotrityl resin using commercially avail-
able building blocks Fmoc-L-propargylglycine (Fmoc-Pra-OH)
and Fmoc-L-azidoalanine (Fmoc-Aza-OH) or Fmoc-L-azido-
homoalanine (Fmoc-Aha-OH) (Scheme 1). CuAAC is incompati-
ble with trityl type resins due to the acidic nature of the reac-
tion medium.32 Linear precursors 1 and 2 were therefore
cleaved from the solid support under acidic conditions and
then 1,4-disubstituted 1,2,3-triazoles 9 and 10 were prepared
by CuAAC-mediated macrocyclisation from the unprotected
precursors 7 and 8 in dilute solution. RuAAC reaction con-
ditions are compatible with SPPS using acid sensitive resins.
Macrocyclisation of linear peptides 1 and 2 was achieved on
solid support using Cp*RuCl(cod) as the catalyst and micro-
wave irradiation (60 °C) to give peptides 5 and 6 in quantitative
conversion as determined by LCMS analysis of a cleaved
Fig. 2 Structure and overlays of energy minimized 3D models of U-II
(4–11) variants 5, 6, 9 and 10 (blue nitrogen, green carbon of U-II(4–11);
grey carbon atoms of 9–10 and 5–6; red oxygen, yellow sulfur atoms).
Models were aligned at the respective Cα and Cβ on residues 5 and 10.
RMSD calculated for the respective Cα and Cβ of residues 5 and 10 at
the compared structures are given in Å. Measured distances (Å) between
the Cα atoms of residues 5 and 10 are shown as pink dashed lines (U-II
(4–11) is 3.95 Å for reference).
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peptide sample. Anhydrous reaction conditions were required
to prevent decomposition of the ruthenium catalyst.
Conversion of starting materials 1 and 2 into macrocyclic pep-
tides 5, 6, 9 and 10 proceeds without a change in molecular
weight, however an significant shift in LC retention time is
observed and was used to determine the reaction progress.
Disappearance of the azide IR absorption band at 2100 cm−1
was also used to confirm conversion of the starting materials
to products. Triazole bridged peptides 5, 6, 9 and 10 were then
purified by reverse-phase HPLC and characterized by analytical
RP-HPLC and ESI-MS.
Biological data
The capacity of U-II(4–11) peptidomimetics 5, 6, 9 and 10, to
act as orthosteric ligands and displace [125I]U-II from recombi-
nant human UTR expressed in CHO cells (CHOhUTR) was
assessed. [125I]U-II was displaced by native U-II in a concen-
tration dependent and saturable manner (Fig. 3). Analysis of
this data set yielded a pIC50 = KD of 9.36 nM for U-II (Table 1).
Peptidomimetics 5 and 6 also displaced [125I]U-II binding,
(Fig. 3) and had essentially identical IC50 = KD values of
around 8 nM. Whilst chemical modification of U-II was toler-
ated there was a loss of affinity of ∼20 fold. Compound 10 dis-
placed [125I]U-II by ∼40% at the highest concentration tested
(1 μM). Compound 9 was inactive (Fig. 3 and Table 1).
Having established that the peptidomimetics bind to the
UTR, we next wanted to determine if this binding caused func-
tional activation of the receptor and resulted in intracellular
calcium release. To achieve this, [Ca2+]i was measured in Fura2
loaded CHOhUTR cells. At 1 µM 5, 6 and 10 produced mono-
phasic increase in [Ca2+]i. Compound 9 was inactive (Fig. 4).
Scheme 1 Synthesis of triazole bridged U-II(4–11) peptidomimetics. Reagents and conditions: (a) (i) 20% piperidine/DMF, 75 °C (MW); (ii) Fmoc-
AA-OH, HCTU, DIEA, DMF, 75 °C (MW); (iii) repeat (i) & (ii); (iv) Ac2O, DIEA, DMF, RT; (b) Cp*RuCl(cod) (20 mol%), DMF, 60 °C (MW), 5 h; (c)
95 : 2.5 : 2.5 TFA/TIS/H2O, RT, 3 h; (d) CuSO4·5H2O, NaAsc, DIEA, H2O, RT, 12 h.
Fig. 3 [125I]U-II binding data; isotope dilution. U-II, compounds 5 and 6
bound to UTR in CHOhUT cells with high (10 nM) affinity. Data are mean
± SEM (n = 5). In these experiments the concentration of [125I]U-II used
was ultra low compared to its KD such that in this paradigm displacer
IC50 = KD.
Table 1 Comparison of [125I]U-II binding to and intracellular calcium
response in CHOhUT cells challenged with U-II and compounds 5, 6, 9
and 10. Novel compounds 5 and 6 were relatively high affinity reversible
UTR agonists
Compound pKi
[125I]U-II binding
reversibility
Intracellular Ca2+
pEC50 Emax (nM)
U-II 9.36 ± 0.19 Irreversible 9.65 ± 0.21 813 ± 200
5 7.98 ± 0.04 Reversible 8.49 ± 0.23 729 ± 66
6 7.96 ± 0.05 Reversible 8.47 ± 0.25 1036 ± 203
9 Inactive Inactive Inactive
10 <6 Not tested <6
Data are mean SEM (n = 5 for binding and 3–4 for [Ca2+]i).
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The increase in [Ca2+]i observed with 5 and 6 was clearly con-
centration dependent and saturable; 10 did not saturate at
1 µM and 9 was inactive. Both 5 and 6 displayed a potency of
∼3 nM and this was ∼15 fold weaker than the native peptide
U-II (Fig. 4 and Table 1). Similar [Ca2+]i data were obtained at
endogenous UTR expressed at low levels in SJCRH30 rhabdo-
myosarcoma cells (ESI Fig. S2†).
The purpose of the chemical modification was to favour
reversibility of binding so we tested this in a wash on-wash off
protocol. CHOhUTR cell membranes were labelled with a fixed
concentration of U-II, 5 or 6. The membranes were then
washed extensively (as in methods), incubated with a fixed
concentration of [125I]U-II and increasing concentrations of
unlabeled U-II added; essentially isotope dilution. Low
binding of [125I]U-II indicated the original U-II challenge has
bound irreversibly leaving few free receptors to which [125I]U-II
could bind. In contrast, the binding of [125I]U-II to membranes
that had been treated with 5 or 6 was indistinguishable from
control untreated membranes; 5 and 6 binding was therefore
reversible (Fig. 5).
Conclusions
In conclusion, novel triazole bridged analogues of U-II have
been computationally designed and prepared using a ruthe-
nium or copper catalyzed macrocyclisation reaction. Biological
evaluation using in vitro [Ca2+]i and [
125I]UII binding assays
demonstrated that compounds 5 and 6 are high affinity UTR
ligands and bind reversibly. These peptidomimetics have pro-
vided new insight into the mechanism of pseudo-irreversible
binding of U-II with the UTR. These data provide evidence that
U-II binds covalently to the UTR. Future investigations in our
laboratories will focus on structural studies to further under-
stand the mechanism of U-II/UTR binding interactions and
the nature of receptor conformation change.
Experimental section
Materials and general methods
Solvents and reagents used in the experiments were purchased
from Novabiochem or Sigma Aldrich and were used without
purification. Fmoc-L-propargylglycine (Fmoc-Pra-OH) and
Fmoc-L-azidoalanine (Fmoc-Aza-OH) were purchased from TCI
and Fmoc-L-azido-homoalanine (Fmoc-Aha-OH) was purchased
from Chiralix. Chloro(pentamethylcyclopentadienyl)(cycloocta-
diene)ruthenium(II) (Cp*RuCl(cod)) catalyst was purchased
from Sigma-Aldrich.
All amino acids used in peptides synthesis were of
L-configuration and were Fmoc protected. All amino acids had
their side chains protected. DMF was dried over 4 Å molecular
sieves and stored under nitrogen.
Solid Phase Peptide Synthesis was performed on a Biotage
Alstra microwave-assisted, automated peptide synthesizer on
0.1 mmol scale. Solvents were evaporated under reduced
pressure on Büchi vacuum rotary evaporators. Peptides were
freeze-dried on a Labconco FreeZone 2.5 lyophiliser.
Analytical RP-HPLC analyses were preformed on a
Gemini™ 5 μm C18 110 Å column (Phenomenex® Inc.,
Torrance, California, 150 mm × 4.6 mm, 5 μm) with a flow rate
of 0.5 mL min−1 using a linear gradient of acetonitrile (0.1%
trifluoroacetic acid (TFA)) in water (0.1% TFA). Retention times
(tR) from analytical RP-HPLC are reported in minutes. Peptides
were purified with a Gemini™ 5 μm C18 110 Å column
(Phenomenex® Inc., Torrance, California, 250 mm × 21 mm,
5 μm, C18) using a specified linear gradient of acetonitrile
(0.1% TFA) in water (0.1% TFA), with a flow rate of 10.6 mL
Fig. 4 Intracellular Ca2+ data. U-II, compounds 5 and 6 and, at high concentrations 10, increased intracellular Ca2+ in CHOhUT cells. The increase
for U-II and compounds 5 and 6 was concentration related and saturable. Data are mean ± SEM (n = 3–4).
Fig. 5 [125I]U-II binding data; reversibility. Binding of compounds 5 and
6 but not U-II to UTR in CHOhUT cells was reversible. Data are from a
typical experiment (n = 5). Mean data are shown in Table 1.
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min−1. UV detection wavelengths in analytical HPLC were
214 nm and 260 nm. UV detection wavelength in semi-prepara-
tive HPLC was 214 nm.
LCMS analysis was performed on a Waters Xevo Q ToF
mass spectrometer coupled to a Water Acquity LC system
with Waters Acquity UPLC BEH C18 column (2.1 × 50 mm).
Solvent system was 0.1% formic acid in MeCN and 0.1%
formic acid in H2O (deionised). Gradient was 5–100% of 0.1%
formic acid in MeCN at 0.6 mL min−1. Mass accuracy was
accomplished by using a reference lock mass scan once per
second. ES cone voltage was 30 V. Collision energy was 4 eV.
MS acquisition rate was 10 spectra per seconds with m/z
range 50–2000 Da.
Peptide synthesis
Peptides were synthesized on a Biotage Alstra automated
microwave-assisted solid-phase peptide synthesizer on
0.1 mmol scale using ChemMatrix 2-chlorotrityl resin (substi-
tution: 0.66 mmol g−1, 100–200 mesh).
Coupling reactions. Fmoc-protected amino acids were made
up as a solution in N,N-dimethylformamide (DMF) (0.2 M)
(5 equiv. relative to the resin loading). The HCTU activator was
prepared as a 0.25 M solution in DMF (5 equiv. relative to the
resin loading). A solution of N,N-diisopropylethylamine (DIEA)
activator base was made up in NMP (1 M) (10 equiv. relative
to the resin loading). The non-native amino acids (0.2 M,
2 equiv.) were coupled using HCTU (0.5 M in DMF, 2 equiv.)
and DIEA (2 M in NMP, 4 equiv.). All amino acids were
coupled at 75 °C (25 W & 1 bar) for 10 min.
Deprotection reactions. A fresh solution of 20% piperidine
in DMF (v/v) containing 0.1 M oxyma pure was prepared for
each peptide. Deprotections were carried out at 75 °C (25 W &
1 bar) for 30 s, followed by a second deprotection using fresh
solution at 75 °C for 3 min.
Acetyl capping. A fresh solution of 20% acetic anhydride in
DMF (15 mL, 0.1 mmol scale) was prepared and added to the
peptide bound resin and heated at 75 °C for 15 min.
Washing procedure: DMF was used for all of the wash
cycles (4 washes between deprotection, coupling and acetyl-
ation reactions).
RuAAC. The resin bound peptide (0.1 mmol) was taken up
in anhydrous DMF (0.5 mL) and the solution degassed with
argon. Ruthenium catalyst [Cp*Ru(cod)] (8 mg, 0.02 mmol,
20 mol%) was added, the reaction vessel flushed with argon
and then heated (MW) at 60 °C for 6 h. After this time the solu-
tion was filtered and the resin was washed with DMF (3 ×
3 mL), MeOH (3 × 3 mL) and then DCM (3 × 3 mL) before
being dried under vacuum for at least 2 h.
CuAAC. Following cleavage from resin and ether precipi-
tation, peptides (0.1 mmol) were dissolved in degassed H2O
(1 mg ml−1) in a RBF. Copper(II) sulfate pentahydrate
(CuSO4·5H2O) (1 equiv.), sodium ascorbate (NaAsc) (1 equiv.)
and DIEA (8 equiv.) were added and the solution mixed for
12 h. The solution was then freeze-dried to remove the
solvent and the crude material purified by semi-preparative
RP-HPLC.
Cleavage test. A small sample of resin (2–3 mg) was
transferred from the bulk reactor to a 1 mL fritted filtration
tube. Cleavage cocktail (TFA/H2O/TIS, 95/2.5/2.5, v/v/v)
(0.5 mL) was added and the red solution was allowed to react
for 1 h. The filtrate was concentrated under a stream of nitro-
gen and dissolved in 50% MeCN/H2O (0.5 mL) for analysis
by MS.
Peptide cleavage and global deprotection. Cleavage cocktail
(TFA/H2O/TIS, 95/2.5/2.5, v/v/v) (5 mL) was added to the resin
and solution was allowed to react for 3 h. The filtrate was col-
lected, concentrated to 0.5 mL under a stream of nitrogen and
precipitated with cold Et2O (15 mL). The tube was spun in a
centrifuge (5000 rpm) and the peptide recovered as a pellet fol-
lowing decanting of the ether solution. This ether wash pro-
cedure was repeated twice and the off-white peptide freeze-
dried from water (5 mL).
Analytical RP-HPLC indicated that all peptides had a purity
of >97%, and the correct molecular weights were confirmed by
LCMS (see ESI†).
Biological data
Radioligand binding. Standard isotope dilution protocols to
determine affinity (KD) are described in detail in ref. 33. In
order to assess reversibility of binding; membranes from
CHOhUTR cells were prepared and incubated with buffer
(control), U-II (100 nM), 5 (100 nM) or 6 (100 nM) for 1 h at RT
as in ref. 33. Membranes were then washed (with centrifu-
gation) three times in large volumes of buffer to remove the
initial ‘challenge’. After this membranes were then incubated
with a fixed concentration of [125I]U-II and increasing concen-
trations of unlabeled U-II; effectively constructing an isotope
dilution curve.33
Intracellular calcium. As described in detail in ref. 29 sus-
pensions of CHOhUT were loaded with 3 μM Fura2 AM for
30 min at 37 °C followed by 20 min de-esterification at room
temperature. 2 mL suspensions of well-washed cells were then
placed into a quartz cuvette and incubated with various con-
centrations of native or chemically modified U-II. Fluorescence
was measured in a PerkinElmer LS5B spectrofluorimeter at
340 and 380 nm excitation; 510 nm emission. Rmax and Rmin
were determined with Titon-X (0.1%) and EGTA (4.5 mM;
pH > 8) and Ca2+ calculated according to ref. 35 using a KD for
Ca2+ of 225 nM.34,35
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